Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ribosomal protein L3 pseudogene is a genomic DNA sequence that is homologous to the gene encoding ribosomal protein L3 but has acquired disabling mutations that prevent it from producing a functional protein product[9][6]. Pseudogenes like this are non-coding and generally do not have known biological functions. They are not considered therapeutic targets, as they do not encode a receptor, enzyme, transporter, or other actionable protein product[9][6]. There may be several such processed pseudogenes scattered through the genome corresponding to the functional ribosomal protein L3 gene[1][3]. The parent gene, ribosomal protein L3 (RPL3), encodes a protein that is an essential component of the 60S ribosomal subunit, involved in protein synthesis[1][3][4]. However, the pseudogene itself does not encode this or any protein and does not participate in the biological or pathological functions of the ribosome or its associated pathways[9][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L3 pseudogene.